Table 1 Baseline demographic, transplant-related characteristics, symptom and treatment-related factors of KTR with COVID-19, i.e., non-survivor vs survivor in KTR with COVID-19
Baseline Demographics and COVID Related Characteristics | Non-survivor (n = 30) | Survivor (n = 188) | P-value |
|---|---|---|---|
1st COVID Wave -n = 16 2nd COVID Wave- n = 14 | 1st COVID Wave -n = 63 2nd COVID Wave -n = 125 | ||
Age n = (> 60(60–71) years:[median-64 yr] < 60 yr(14–60)[median -40 yr] | (8:22) | (15:173) | 0.006 |
Sex (Male: Female) | 23:7 | 146: 42 | 0.90 |
Blood Group (% within Blood Grp) | 0.04 | ||
O | 9 (30%) | 39(20.74%) | |
B | 16 (53.33%) | 71(37.76%) | |
AB | 3(10%) | 19(10.11%) | |
A | 2 (6.66%) | 59(31.38%) | |
Living donor (n = 167) Vs deceased donor (n = 51) | 21(70%) vs 9(30%) | 146(77.65%) vs 42(22.34%) | 0.39 |
Post-transplant duration Median (months) min–max | 48.5(3–220) | 54(0–234) | 0.47 |
Interquartile range (25–50-75) | (28.25–48.5–97.25) | (24–54-86) | |
Diabetes | 12 (40%) | 44 (23.40%) | 0.05 |
Hypertension | 28 (93.33%) | 172(91.49%) | 1 |
ATG induction | 13 (43.33%) | 107(56.91%) | 0.17 |
Delayed graft function | 2 (6.66%) | 9(4.78%) | 0.65 |
History of treatment for acute rejection in last three-month preceding COVID-19 infection | 7 (23.33%) | 20 (10.63%) | 0.06 |
History of treatment for tuberculosis | 4(13.33%) | 22(11.70%) | 0.76 |
Recurrent infection and antimicrobial therapy | 7(23.33%) | 34(18.08%) | 0.46 |
History of hepatitis C infection | 2(6.66%) | 23(12.23%) | 0.54 |
Baseline serum creatinine(mg/dl) Median min–max | 1.45(0.8–7) | 1.2(0.4–4.8) | 0.002 |
Interquartile range | (1–1.45–1.85) | (1–1.2–1.4) | |
Creatinine at presentation(mg/dl) Median Min–Max | 3.05(0.76 -9.2) | 1.3(0.3–7.5) | 0.0001 |
Interquartile range | (1.80–3.05–4.12) | (1–1.3–1.7) | |
Fever | 26(86.66%) | 160(85.11%) | 1 |
Myalgia | 20(66.66%) | 130(69.15%) | 0.83 |
Cough | 16 (53.33%) | 76 (40.42%) | 0.23 |
Dyspnea | 14 (46.66%) | 48(25.53%) | 0.02 |
Diarrhea | 12 (40%) | 28 (14.89%) | 0.001 |
Loss of smell/ageusia | 0 | 10(5.31%) | 0.36 |
Community vs Hospital-acquired | 28(93.33%) vs 2(6.66%) | 181(96.28%) vs 7(3.72%) | 0.35 |
Coinfection at time of COVID-19 | 9 (30%) | 18(9.57%) | 0.002 |
Lymphopenia at admission | 13(43.33%) | 31(16.49%) | 0.001 |
CT CORAD¥ score of 4 or more | 27(90%) | 53(28.19%) | 0.0001 |
Received antibiotics | 28(93.33%) | 139(63.76%) | 0.019 |
Antimetabolite reduced or stopped | 27(90%) | 161(85.63%) | 0.77 |
CNI stopped | 23(76.66%) | 38(20.21%) | 0.001 |
Increase in steroids | 14(46.66%) | 53(28.19%) | 0.38 |
On Going Graft dysfunction | 20(66.66%) | 35(18.61) | 0.0001 |
Biopsy-proven acute rejection within three-month period of COVID-19 infection | 7(23.33%) | 10(5.31%) | 0.003 |
Acute kidney Injury | 17(56.66%) | 29(15.42%) | 0.0001 |
RRT® during COVID in KTR | 13(43.33%) | 11(5.85%) | 0.0001 |
Oxygen requirements | 30(100.0%) | 45(23.93%) | 0.0001 |
Intubation and mechanical ventilation | 23(76.66.5%) | 2(1.06%) | 0.0001 |
Graft loss | 3(10%) | 7(3.72%) | 0.14 |
Hospitalisation vs home care | 27(90%) vs 3 (10%) | 108(57.44%) vs 80(42.55%) | 0.0001 |
Recurrent COVID (n = 2) | 1(3.33%) | 1(0.53% | 0.25 |